ライフサイエンスコーパス: ARS

1 ARS is genetically associated with mutations in the PITX

2 ARS-1620 (G12C-specific inhibitor) disrupts the KRAS(G12

3 ARSs are ubiquitously expressed, essential enzymes respo

4 idence interval (CI), 0.93-0.95, P < 0.0001; ARS >=3: adjusted HR 0.93, 95% CI, 0.91-0.95, P < 0.0001

5 Corresponding proteins for the 17 ARS genes were identified in the platelet proteome, of w

6 reshold to define high-volume centers and 20 ARS points the best threshold to define high-risk patien

7 To date, biallelic mutations in 31 ARS genes are known to cause recessive, early-onset seve

8 xpression of ARSs, mutations in 32 of the 37 ARS-encoding loci cause severe, early-onset recessive ph

9 ad anticholinergic exposure (ARS 1-2, 15.6%; ARS >=3, 13.6%).

10 gradients: phenylalanyl-RS (FRS), and the 9 ARSs that form the multi-ARS complex (MSC).

11 onary function test results before and after ARS revealed that of 5 patients, 4 (80%) had improvement

12 s after ARS; however, at 3 to 4 months after ARS, pH monitoring was still pathological in 18% of pati

13 S to 0.7% (P < 0.001) at 3 to 4 months after ARS; however, at 3 to 4 months after ARS, pH monitoring

14 implement routine long-term follow-up after ARS in pediatric patients with gastroesophageal reflux d

15 at 1 to 5 years, and at 10 to 15 years after ARS, 81%, 80%, and 73% of patients, respectively, were c

16 At 10 to 15 years after ARS, the number of patients with pathological reflux had

17 ts were symptom free at 10 to 15 years after ARS.

18 ss of the location of CARE enhancer, for all ARS genes there was constitutive association of RNA poly

19 being more efficient, only DS can act as an ARS in long-term assays.

20 deletion of DS, Raji ori could now act as an ARS in the long term.

21 ing sequences (ARSs) in eukaryotic cells, an ARS consensus sequence (ACS) has emerged for budding yea

22 In this Protocol Extension, an ARS is inserted into the TAR vector along with a counter

23 lex class I and II molecules may generate an ARS-specific autoimmune response, which may be responsib

24 Deletion mapping of an ARS element linked to the HO gene of Saccharomyces cerev

25 f streptococcal protein G, so called REX and ARS ligands with proved high affinity and selectivity to

26 istal to the upper esophageal sphincter) and ARS.

27 gression and calculated operative volume and ARS thresholds defining high-volume centers and high-ris

28 features common to both DNA polymerases and ARSs are the use of multidomain architectures that segre

29 as from mutations in mitochondrial tRNAs and ARSs.

30 ed; interestingly, the expression of another ARS-associated gene, pitx2, was responsive to the estima

31 between the inflammatory myopathies and anti-ARS antibodies implies a role for the ARS molecules in t

32 Current artesunate (ARS) regimens for severe malaria are complex.

33 tion of transcripts encoding arylsulfatases (ARS), an extracellular polypeptide that may be important

34 t Raji ori, binds EBNA1; whereas both act as ARSs in short-term assays, with DS being more efficient,

35 More origins can initially act as ARSs than can be established.

36 n the roles of tRNA-binding proteins such as ARSs in this process.

37 the newest bovine reference genome assembly, ARS-UCD1.2, as well as the previous reference genome, UM

38 cytoplasmic tRNA synthetases and associated ARS-interacting multifunctional protein genes.

39 Atypical ARS was defined as lack of symptoms or signs, a single s

40 h typical ARS in 202 (70%) and with atypical ARS in 88 (30%) patients.

41 Patients with atypical ARS were hospitalized 4 times more often compared with t

42 osed slightly earlier compared with atypical ARS, but this difference was not significant (P = .3).

43 me significantly decreased from 13.4% before ARS to 0.7% (P < 0.001) at 3 to 4 months after ARS; howe

44 whose samples had AR-V7-positive CTCs before ARS inhibition had resistant posttherapy PSA changes (PT

45 fic marker for response and outcomes between ARS inhibitors and taxanes.

46 l-tRNA synthetase (GluProRS), a bifunctional ARS of the MSC, has a regulated, noncanonical activity t

47 idation of alizarin red s (ARS) in the boron-ARS complex at MNP/CNT/GCE and the oxidation of tiron in

48 terial-yeast shuttle plasmid deleted of both ARS and CEN elements.

49 n of the solution pH and the pK(a)'s of both ARS and the arylboronic acid.

50 Phenylboronic acid (PBA) binds to both ARS and HbA1c via diol-boronic acid complexation.

51 The essential 11-bp ARS consensus sequence (ACS) that binds the origin recog

52 and increased CRF mRNA expression induced by ARS were restored by icv-injection of OXT.

53 enesis, it is unclear how mutant forms cause ARS dental anomalies.

54 egative human PITX2A K50E allele also caused ARS-like phenotypes.

55 Both yeast single-copy CEN/ARS and high-copy 2micro shuttle plasmids can be isolate

56 r comprehensively mapping and characterizing ARSs within a yeast genome.

57 Chordate ARSs have evolved distinctive features absent from ances

58 parent in the 228 phylogenetically conserved ARS elements among the six sensu stricto Saccharomyces s

59 contribute to the neural circuit controlling ARS in the nematode Caenorhabditis elegans.

60 ics reveals that ten of the twenty cytosolic ARSs associate with ribosomes in sucrose gradients: phen

61 a plausible explanation to the differential ARS activity observed in our previous mcm1-1 mutant expe

62 rent understanding of recessive and dominant ARS-mediated disease.

63 In contrast, dominant ARS-mediated diseases specifically affect the peripheral

64 We found that a suppressor element (ARS), previously identified in mouse AR and located in t

65 Ablation of dopaminergic neurons eliminated ARS behavior, as did application of the dopamine recepto

66 signated ARS1 and ARS2) were found to encode ARS enzymes capable of accepting a variety of fatty acyl

67 Interestingly, mutations in genes encoding ARS enzymes have been implicated in a broad spectrum of

68 Variants in genes encoding ARS enzymes lead to myriad human inherited diseases.

69 y several rice (Oryza sativa) genes encoding ARSs, which are likely involved in the production of def

70 iduals, 71,569 had anticholinergic exposure (ARS 1-2, 15.6%; ARS >=3, 13.6%).

71 eterozygosity for missense mutations in five ARS genes, which points to a shared mechanism of disease

72 We propose a mechanism for ARS in C. elegans in which dopamine, released in respons

73 ain-of-function mechanism is responsible for ARS-mediated neuropathy, or if a combination of these me

74 rep, was identified that can substitute for ARS, and multiple elements, termed mtc, could substitute

75 We identified one requirement for ARSs to be established: They must function efficiently e

76 Based on these data, KARS becomes the fourth ARS gene associated with CMT disease, indicating that th

77 Furthermore, ARS was affected by mutations in the glutamate receptor

78 eviously proven safe and effective against H-ARS when administered (via the oral (po) or intramuscula

79 may be an ideal countermeasure to mitigate H-ARS following accidental radiation exposure.

80 Hematopoietic acute radiation syndrome (H-ARS) and delayed effects of acute radiation exposure (DE

81 ed Hematopoietic Acute Radiation Syndrome (H-ARS) and increased survival in mice.

82 Hematopoietic acute radiation syndrome (H-ARS) is characterized by severe myelosuppression, which

83 es individuals at low (ARS < or =1) or high (ARS > or =4) likelihood of complete resolution of hypert

84 c characteristics, and comorbidities, higher ARS scores were associated with longer LOS [smaller haza

85 cs accorded similar mean ARS (IFD); however, ARS for aggregated individuals declined near the periphe

86 However, ARSs and tRNAs also perform noncanonical functions that

87 large-scale mutation screen of the 37 human ARS genes in a cohort of 355 patients with a phenotype c

88 enamel hypoplasia-consistent with the human ARS phenotype.

89 ression, secretion and interactions in human ARSs, revealing hidden biological functions beyond their

90 iology and therapeutic applications of human ARSs in diseases including autoimmune and rare diseases,

91 Class II ARS possess a unique catalytic domain fold, possess acti

92 facial region, the classic sites affected in ARS.

93 anscriptional mechanism that is defective in ARS.

94 s where the animals predominantly engaged in ARS behaviour were identified in both study areas.

95 ayed GE and increased CRF mRNA expression in ARS were abolished by icv-injection of BMI.

96 rturbed by missense PITX2 mutations found in ARS patients.

97 on intraocular pressure (IOP) management in ARS.

98 derpinnings of the enamel defect observed in ARS patients who carry PITX2 mutations.

99 Mutations in ARSs have emerged as a cause of recessive, often complex

100 Bi-allelic mutations in ARSs typically cause severe, early-onset, recessive dise

101 Transfection of constructs that included ARS element into AD cells reduced the transactivating ac

102 Increasing ARS scores were associated with increased LOS, decreased

103 It is suggested that central OXT inhibits ARS-induced CRF mRNA expression via GABA(A) receptors in

104 re excluded because they were not initiating ARS or taxane therapy; and 18 were excluded for processi

105 ave resulted in the most recent interaction, ARS-1620, which demonstrates selective inhibition of K-R

106 children to receive a total dose of 12 mg/kg ARS as either a control regimen of five i.m. injections

107 f the genes encoding mitochondrial-localized ARSs were weakly induced.

108 smaller hazard ratios (HRs) mean longer LOS; ARS 1-2: adjusted HR 0.94, 95% confidence interval (CI),

109 one deacetylase inhibitors restored the lost ARS-binding complex.

110 A mutant designated ars73a exhibited low ARS activity and failed to show increases in ECP76, LHCB

111 RS accurately identifies individuals at low (ARS < or =1) or high (ARS > or =4) likelihood of complet

112 synthetic DNA sequences that retain maximal ARS function.

113 socio-spatial tactics accorded similar mean ARS (IFD); however, ARS for aggregated individuals decli

114 e readily applied to understand and modulate ARS function in diverse systems.

115 ; in absence of fever, presence of 2 or more ARS symptoms or signs.

116 RS (FRS), and the 9 ARSs that form the multi-ARS complex (MSC).

117 First, a battery of known and novel ARS inhibitors was tested against Plasmodium falciparum

118 lid GE was measured under non-stressed (NS), ARS and CHS conditions.

119 earch (ARS) during foraging, but only 42% of ARS were associated with fishing vessels, indicating muc

120 odeling measured the adjusted association of ARS with LOS (primary outcome), institutional discharge,

121 bryologic techniques to study the biology of ARS in a zebrafish model that uses transgenes to mark ne

122 and recapitulates ocular characteristics of ARS, including corneal and iris stroma maldevelopment.

123 The deletion of ARS resulted in an eightfold increase in AR-promoter act

124 l phage M13 vector which allows detection of ARS (autonomously replicating sequence) function in clon

125 scanning to define molecular determinants of ARS function with single-nucleotide resolution.

126 his finding explains the frequent failure of ARS assays in mammalian cells.

127 pand the locus and clinical heterogeneity of ARS-related clinical phenotypes, and further support imp

128 ng of the allelic and locus heterogeneity of ARS-related disease is incomplete.

129 eplication origins and causes instability of ARS-containing plasmids.

130 scription and demonstrates the first link of ARS with defective PITX2 protein interactions.

131 binding in vitro correlated with the loss of ARS activity in vivo.

132 ons for defining the molecular mechanisms of ARS mutations toward designing therapies for affected pa

133 es zebrafish a potentially powerful model of ARS, amenable to in vivo experimentation and development

134 the enamel defect in a novel mouse model of ARS.

135 Studies on short-term outcome of ARS in pediatric patients with gastroesophageal reflux d

136 The outcomes of ARS included symptomatic improvement.

137 The proportion of ARS behaviours associated with fishing boats were higher

138 ssible mechanism for the previous reports of ARS in patients with balanced translocations involving t

139 Screening of ARS patients identified an approximately 7600-kb deletio

140 d for the recovery and semiquantification of ARS in a stained monolayer by acetic acid extraction and

141 Here, we review our current understanding of ARS-associated disease phenotypes and discuss potential

142 tural differences in the catalytic clefts of ARSs from pathogens and humans.

143 s flanking the minimal functional domains of ARSs.

144 ential function and ubiquitous expression of ARSs, mutations in 32 of the 37 ARS-encoding loci cause

145 This historical function of ARSs and tRNAs is fairly well understood.

146 dy of research emphasizing the importance of ARSs in multisystem disease and significantly expands th

147 Here, we review the inhibition of ARSs by small molecules, including the various families

148 To further explore the role of ARSs in CMT disease, we performed a large-scale mutation

149 cm1-1 mutant can be overcome for a subset of ARSs by the inclusion of flanking sequences.

150 Pathogenic variants of ARSs have been previously associated with peripheral neu

151 Thanks to the wealth of details on ARS structures and functions and the growing appreciatio

152 ave the way for further in-depth research on ARS related recessive disorders and precision therapies.

153 Replication origins (ARSs) at internal Y' elements were found to fire in earl

154 RS and the MSC, and to a lesser extent other ARSs, localize to translating ribosomes, most strikingly

155 ith superior survival on taxane therapy over ARS-directed therapy in a clinical practice setting.

156 Parenteral ARS is associated with a risk of delayed anemia in Afric

157 e-dose i.m. and a three-dose i.v. parenteral ARS regimen with the standard five-dose regimen using a

158 men with mCRPC, 191 were evaluable (128 pre-ARS inhibitor and 63 pretaxane).

159 dividuals were young adults better predicted ARS, but network metrics for younger animals, particular

160 formation, and represses initiation at rDNA ARSs.

161 arging as the primary mechanism of recessive ARS-related disease.

162 nRNP L binds to this ARS motif and regulates ARS-containing exons; however, hnRNP L does not function

163 ompared to subjects with previously reported ARS-related diseases, individuals with bi-allelic CARS v

164 tors, blocked induction of the AA-responsive ARS genes.

165 pture efficiency of model THP-1 cells on REX/ARS surfaces and practically no cell binding on control

166 an aminoacyl-tRNA synthetase-like ribozyme (ARS ribozyme), which was evolved in vitro.

167 f the commercially available alizarin red S (ARS) chemosensor with the nanomaterial, translating its

168 The oxidation of alizarin red s (ARS) in the boron-ARS complex at MNP/CNT/GCE and the oxi

169 Alizarin red s (ARS) is used as a redox indicator.

170 Alizarin red S (ARS) staining has been used for decades to evaluate calc

171 -containing, fluorescent dye Alizarin Red S (ARS) was probed.

172 tified using the Anticholinergic Risk Scale (ARS).

173 lting 4-item aldosteronoma resolution score (ARS), 3 likelihood levels for complete resolution were i

174 We built an Adrenalectomy-risk score (ARS) from logistic regression and calculated operative v

175 tes-directed flight, area-restricted search (ARS) and resting-and model the probability of transition

176 ntify transiting and area-restricted search (ARS) behaviours, believed to indicate foraging activitie

177 viduals exhibited an Area-Restricted Search (ARS) during foraging, but only 42% of ARS were associate

178 Area-restricted search (ARS) is a foraging strategy used by many animals to loca

179 e local sampling and area-restricted search (ARS) rely on flexible movements.

180 theoretical work on area-restricted search (ARS) that links turning-angle and step-size changes to g

181 developing novel biologics from the secreted ARS proteins or their parts.

182 on of the autonomously replicating sequence (ARS) and centromere (CEN) elements that are normally bot

183 reliable autonomously replicating sequence (ARS) assay for isolating potential replicators, the iden

184 The yeast autonomously replicating sequence (ARS) assay has been a valuable tool in dissecting replic

185 erevisiae autonomously replicating sequence (ARS) consensus, raising the question of how they are rec

186 ncodes 11 autonomously replicating sequence (ARS) elements that function as chromosomal replicators.

187 cation of autonomously replicating sequence (ARS)-containing plasmids in yeast cells.

188 riched in autonomously replicating sequence (ARS)-like sequences, elements that function as the origi

189 The activation-responsive sequence (ARS) motif has previously been identified in several exo

190 o define autonomously replicating sequences (ARSs) in eukaryotic cells, an ARS consensus sequence (AC

191 o detect autonomously replicating sequences (ARSs) in human cells.

192 with the USDA Agricultural Research Service (ARS), is a comparative legume resource that integrates g

193 o administer an androgen receptor signaling (ARS) inhibitor or a taxane.

194 enes named the "aspirin response signature" (ARS) was associated with PFS in HV1 (r = -0.31, p = 0.03

195 One SNP "ARS-BFGL-BAC-27914" reached Bonferroni genome wide signi

196 contained proteins that produced a specific, ARS-binding complex, while this complex appeared to have

197 ying (GE) induced by acute restraint stress (ARS) for 90 min is completely restored following 5 conse

198 er they predict annual reproductive success (ARS) or longevity among adult female spotted hyenas Croc

199 varied in their annual reproductive success (ARS).

200 drome component of acute radiation syndrome (ARS) results from depletion of immature parenchymal stem

201 Typical acute retroviral syndrome (ARS) was defined as fever plus at least 1 symptom or sig

202 on associated with Axenfeld-Rieger syndrome (ARS) demonstrates reduced phosphorylation.

203 ma associated with Axenfeld-Rieger Syndrome (ARS) is poorly described in the literature.

204 Axenfeld-Rieger syndrome (ARS) patients with PITX2 point mutations exhibit a wide

205 Patients with Axenfeld-Rieger Syndrome (ARS) present various dental abnormalities, including hyp

206 X2 associated with Axenfeld-Rieger syndrome (ARS) provided the first link of this homeodomain transcr

207 eye, most commonly Axenfeld-Rieger syndrome (ARS), often with other systemic features.

208 re associated with Axenfeld-Rieger syndrome (ARS), which involves ocular, dental, and umbilical abnor

209 re associated with Axenfeld-Rieger syndrome (ARS).

210 nt of one or more alkylresorcinol synthases (ARSs), type III polyketide synthases (PKSs) that produce

211 o their canonical role in protein synthesis, ARSs are also involved in RNA splicing, transcriptional

212 Here, we examine tRNA-aminoacyl synthetase (ARS) localization in protein synthesis.

213 abnormalities in aminoacyl t-RNA synthetase (ARS) genes are linked to various unique leukodystrophies

214 ubunit of a multi-aminoacyl-tRNA synthetase (ARS) complex, has also been reported to stabilize p53 vi

215 potential of the aminoacyl-tRNA synthetase (ARS) family as a source of antimalarial drug targets.

216 ion of the entire aminoacyl-tRNA synthetase (ARS) gene family revealed that 16/20 of the genes encodi

217 ations in several aminoacyl-tRNA synthetase (ARS) genes have been implicated in inherited CMT disease

218 omponents are the aminoacyl tRNA synthetase (ARS) molecules.

219 Aminoacyl-tRNA synthetases (ARS) are ubiquitously expressed, essential enzymes that

220 Aminoacyl tRNA synthetases (ARS) catalyze the ligation of amino acids to cognate tRN

221 Aminoacyl-tRNA synthetases (ARSs) are critical for protein translation.

222 Aminoacyl-tRNA synthetases (ARSs) are essential enzymes for protein synthesis with e

223 Aminoacyl-tRNA synthetases (ARSs) are essential enzymes responsible for charging tRN

224 Aminoacyl-tRNA synthetases (ARSs) are responsible for charging amino acids to cognat

225 Aminoacyl-tRNA synthetases (ARSs) are ubiquitous, ancient enzymes that charge amino

226 Aminoacyl-tRNA synthetases (ARSs) are universal enzymes that catalyze the attachment

227 Aminoacyl-tRNA synthetases (ARSs) catalyze the attachment of specific amino acids to

228 Aminoacyl-tRNA synthetases (ARSs) catalyze the attachment of specific amino acids to

229 Aminoacyl-tRNA synthetases (ARSs) function to transfer amino acids to cognate tRNA m

230 e genes encoding aminoacyl-tRNA synthetases (ARSs) have been implicated in CMT disease primarily asso

231 Aminoacyl-tRNA synthetases (ARSs) join amino acids to their cognate tRNAs to initiat

232 Aminoacyl tRNA synthetases (ARSs) link specific amino acids with their cognate trans

233 In translation aminoacyl-tRNA synthetases (ARSs) recognize the identities of tRNAs and charge them

234 polymerases and aminoacyl-tRNA synthetases (ARSs) represent large enzyme families with critical role

235 tated by cognate aminoacyl-tRNA synthetases (ARSs), which bind tRNAs and ligate them to their corresp

236 The PITX2 T68P ARS mutant protein physically interacts with FoxJ1; howe

237 cupancy of Mcm1 in the C domain of telomeric ARSs is required for efficient initiation.

238 BV, functions in vivo but fails in long-term ARS assays.

239 reased, to be in directed flight rather than ARS.

240 It was shown that ARS preferentially reacted with the boronic (neutral, tr

241 Recent data suggest that ARS molecules and their proteolytic fragments generated

242 Multi-omic studies have revealed that ARSs interact with both viral proteins and RNAs and pote

243 The ARS accurately identifies individuals at low (ARS < or =

244 The ARS was associated with death or MI in both patient coho

245 evidence that explores the links between the ARS molecules, inflammation, and apoptosis, with the aim

246 differ for different exons that contain the ARS core motif.

247 d anti-ARS antibodies implies a role for the ARS molecules in the pathogenesis of these syndromes.

248 oxidative stress, JTV1 dissociates from the ARS complex, translocates to the nucleus, associates wit

249 er either upstream of or downstream from the ARS consensus sequence (ACS).

250 r keratoderma, and recently mutations in the ARS (component) B gene have been identified in families

251 ngs support the notion that mutations in the ARS gene are pathogenic in mal de Meleda.

252 qter, and in a recent study mutations in the ARS gene have been identified in families with this diso

253 ch two different homozygous mutations in the ARS gene were identified.

254 have distinct coordination properties in the ARS ribozyme.

255 p </= 0.0002) was improved by including the ARS or 1 of its genes, ITGA2B.

256 monstrate that AA availability modulates the ARS gene family through modulation of transcription elon

257 Expression of the ARS dominant negative human PITX2A K50E allele also caus

258 Several of the ARS molecules and their proteolytic fragments generated

259 sis of the best characterized context of the ARS motif, namely the ESS1 sequence from CD45 exon 4, to

260 indicate a mechanism for the activity of the ARS mutant proteins in specific cell types and provides

261 Saccharomyces cerevisiae ORC recognizes the ARS (autonomously replicating sequence) consensus sequen

262 onstrate that different mutations within the ARS motif affect specific aspects of regulatory function

263 t EPRS acted as an integrated node among the ARSs in various cardiac pathogenic processes.

264 hnRNP L binds to this ARS motif and regulates ARS-containing exons; however, h

265 ulation along a spectrum ranging from LDT to ARS.

266 The binding of PBA to ARS shifts its redox potential negatively.

267 hout detectable AR-V7-positive CTCs prior to ARS inhibition.

268 showed superior OS with taxanes relative to ARS inhibitors when AR-V7-positive CTCs were detected pr

269 ract to refluxate; these patients respond to ARS despite negative pH test results.

270 s of many amino acids provide a challenge to ARSs.

271 ith a ROS-inducer, such as arsenic trioxide (ARS), N-(4-hydroxyphenyl) retinamide (HPR) or dithiophen

272 ids to defined anticodon sequences in tRNAs, ARSs are essential to the physical interpretation of the

273 zed 4 times more often compared with typical ARS (43% vs 11%; P < .001).

274 PHI manifested with typical ARS in 202 (70%) and with atypical ARS in 88 (30%) patie

275 Patients with typical ARS were diagnosed slightly earlier compared with atypic

276 proximal exposure who subsequently underwent ARS, 13 patients (81%) had resolution of cough and 3 pat

277 Of 20 patients who subsequently underwent ARS, asthma symptoms improved in 18 (90%), and 6 of them

278 least 5 times a day, subsequently underwent ARS.

279 versity analysis was carried out on the USDA-ARS C. baccatum germplasm collection using data from GIS

280 k Resource (TOGR panel) and 89 from the USDA-ARS National Clonal Germplasm Repository (NCGR panel) in

281 SoyBase, the USDA-ARS soybean genetic database, is a comprehensive reposit

282 20 wild/exotic clones maintained at the USDA-ARS Sugarcane Research Unit in Houma, Louisiana.

283 the USDA/Agricultural Research Service (USDA/ARS), and the Eunice Kennedy Shriver National Institute

284 g a summary of a workshop hosted by the USDA/ARS Children's Nutrition Research Center and summary rep

285 ies for the development of clinically useful ARS inhibitors are emerging to manage microbial and para

286 erentially affect tissues depending on which ARS is mutated.

287 llaborate in the repair of the genome, while ARSs provide aminoacylated tRNA precursors for protein s

288 re found to fire in early-mid-S phase, while ARSs at the terminal Y' elements were confirmed to fire

289 is for developmental defects associated with ARS patients.

290 are not considered typically associated with ARS, or occurrence of an opportunistic disease.

291 n typically considered to be associated with ARS; in absence of fever, presence of 2 or more ARS symp

292 However, when HbA1c competes with ARS for PBA binding, the solution potential shifts posit

293 al-based practice of patients diagnosed with ARS between 1973 and 2018.

294 In 32 patients identified with ARS (median age at presentation 6.9 years, 0-58.7 years;

295 esulted in the most recent interaction, with ARS-1620, which demonstrates selective inhibition of K-R

296 ur series, greater than 70% of patients with ARS have secondary glaucoma that often requires multiple

297 However, the treatment of patients with ARS remains mostly supportive and palliative.

298 Here, we dissected two conserved telomeric X ARSs, ARS120 (XARS6L) and ARS131a (XARS7R), that replica

299 An unfired Y' ARS, an inserted foreign (bacterial) sequence, and, as p

300 (HPV16) genome that can substitute for yeast ARS and CEN elements.